#AS­CO21: No­var­tis keeps build­ing out sur­vival da­ta for Kisqali, hop­ing to add pres­sure on Pfiz­er's Ibrance

As No­var­tis’ Kisqali for breast can­cer trails Pfiz­er’s Ibrance in sales, the Swiss bio­phar­ma con­tin­ues to trot out long-term sur­vival da­ta it hopes will flesh out the drug’s over­all pro­file.

Ahead of #AS­CO21 this week­end, No­var­tis teased out more da­ta for the CDK4/6 in­hibitor for post­menopausal HR-pos­i­tive, HER2-neg­a­tive metasta­t­ic breast can­cer pa­tients. With more than four years of fol­low-up, Kisqali in com­bi­na­tion with As­traZeneca’s Faslodex pro­vid­ed more than a year of ex­tra sur­vival ben­e­fit com­pared to Faslodex alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER